Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.29
-0.04-3.01%
At close: -
$1.31
0.021.54%
After Hours: 4:06 PM EDT
Comments
Loading...
Galectin Therapeutics Analyst Ratings and Price Targets | NASDAQ:GALT | Benzinga
Galectin Therapeutics Inc has a consensus price target of - based on the ratings of 1 analysts. The high is issued by on . The low is issued by on . The 3 most-recent analyst ratings were released by HC Wainwright & Co. on November 15, 2024, August 16, 2024, and April 9, 2024, respectively. With an average price target of $11 between HC Wainwright & Co., there's an implied 739.76% upside for Galectin Therapeutics Inc from these most-recent analyst ratings.
Analyst Ratings for Galectin Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/02/2025 | Buy Now | — | HC Wainwright & Co. | Ed Arce57% | — | Reiterates | Neutral → Neutral | Get Alert |
| 12/27/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce57% | — | Downgrade | Buy → Neutral | Get Alert |
| 11/15/2024 | Buy Now | 739.76% | HC Wainwright & Co. | Ed Arce57% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2024 | Buy Now | 739.76% | HC Wainwright & Co. | Ed Arce57% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 739.76% | HC Wainwright & Co. | Ed Arce57% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 04/01/2024 | Buy Now | 739.76% | HC Wainwright & Co. | Ed Arce57% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 739.76% | HC Wainwright & Co. | Ed Arce57% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2023 | Buy Now | 739.76% | HC Wainwright & Co. | Ed Arce57% | → $11 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2023 | Buy Now | 739.76% | HC Wainwright & Co. | Ed Arce57% | → $11 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Galectin Therapeutics (GALT) stock?
The latest price target for Galectin Therapeutics (NASDAQ:GALT) was reported by HC Wainwright & Co. on April 2, 2025. The analyst firm set a price target for $0.00 expecting GALT to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Galectin Therapeutics (GALT)?
The latest analyst rating for Galectin Therapeutics (NASDAQ:GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their neutral rating.
When was the last upgrade for Galectin Therapeutics (GALT)?
There is no last upgrade for Galectin Therapeutics
When was the last downgrade for Galectin Therapeutics (GALT)?
The last downgrade for Galectin Therapeutics Inc happened on December 27, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Galectin Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Galectin Therapeutics (GALT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
Is the Analyst Rating Galectin Therapeutics (GALT) correct?
While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $0.00 to $0.00. The current price Galectin Therapeutics (GALT) is trading at is $1.31, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
